The Chun Lab
Publications Partnerships Funding Contact
Somatic Genomic Mosaicism Lysophospholipid Receptors and Signaling Single-Cell Transcriptomics Neuroscience Drug Discovery
Current Lab Members Past Lab Members Lab Fun Join Us
News Media Multimedia
Research Somatic Genomic Mosaicism Lysophospholipid Receptors and Signaling Single-Cell Transcriptomics Neuroscience Drug Discovery Publications Team Current Lab Members Past Lab Members Lab Fun Join Us Media News Media Multimedia PartnershipsFundingContact
The Chun Lab
A Mechanistically Novel, First Oral Therapy for Multiple Sclerosis: The Development of Fingolimod (FTY720, Gilenya)
Type: Review, Year: 2011, PublicationsScienceSitesJune 4, 2021S1P, Multiple Sclerosis
Facebook0 Twitter LinkedIn0 Reddit Tumblr 0 Likes
Previous

FTY720 (Fingolimod) Efficacy in an Animal Model of Multiple Sclerosis Requires Astrocyte Sphingosine 1-Phosphate Receptor (S1P1) Modulation

Type: Article, Year: 2011, Publications, Highlighted ArticlesScienceSitesJune 4, 2021S1P, Multiple Sclerosis
Next

Mechanisms of Fingolimod’s Efficacy and Adverse Effects in Multiple Sclerosis

Type: Review, Year: 2011, PublicationsScienceSitesJune 4, 2021S1P, Multiple Sclerosis
Lab News
Tiny brain bubbles carry complete codes
Tiny brain bubbles carry complete codes

April 9, 2024

Similarity between vitamin B12 loss and multiple sclerosis revealed
Similarity between vitamin B12 loss and multiple sclerosis revealed

December 11th, 2023

Yasuyuki Kihara wins a dream award
Yasuyuki Kihara wins a dream award

November 12th, 2022

Sanford Burnham Prebys unravels mysteries of the aging Down syndrome brain
Sanford Burnham Prebys unravels mysteries of the aging Down syndrome brain

November 15th, 2021

Sanford Burnham Prebsys Medical Discovery Institute
 
 

© 2021 The Chun Lab | Designed & developed by ScienceSites